Evidence map›Paper›PMID 32180206›Full record

ArticleHuman cell2020

Kasumi leukemia cell lines: characterization of tumor genomes with ethnic origin and scales of genomic alterations.

Fumio Kasai, Hiroya Asou, Midori Ozawa, Kazuhiko Kobayashi, Hiroyuki Kuramitsu, Motonobu Satoh, Arihiro Kohara, Yasuhiko Kaneko, Machiko Kawamura

Open access · hybridAbstract read
In one paragraph

Article in Human cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research.International journal of molecular sciences · 2023
    Review
  7. The LL-100 Cell Lines Panel: Tool for Molecular Leukemia-Lymphoma Research.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Fumio KasaiJapanese Collection of Research Bioresources (JCRB) Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition, Saito-Asagi 7-6-8, Ibaraki, Osaka, 567-0085, Japan. k-230@umin.ac.jp.
Hiroya AsouMedicine Development Unit, Eli Lilly, Kobe, 651-0086, Japan.
Midori OzawaJapanese Collection of Research Bioresources (JCRB) Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition, Saito-Asagi 7-6-8, Ibaraki, Osaka, 567-0085, Japan.
Kazuhiko KobayashiDepartment of Clinical Laboratory, Saitama Cancer Center, Saitama, 362-0806, Japan.
Hiroyuki KuramitsuDepartment of Clinical Laboratory, Saitama Cancer Center, Saitama, 362-0806, Japan.
Motonobu SatohJapanese Collection of Research Bioresources (JCRB) Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition, Saito-Asagi 7-6-8, Ibaraki, Osaka, 567-0085, Japan.
Arihiro KoharaJapanese Collection of Research Bioresources (JCRB) Cell Bank, National Institutes of Biomedical Innovation, Health and Nutrition, Saito-Asagi 7-6-8, Ibaraki, Osaka, 567-0085, Japan.
Yasuhiko KanekoResearch Institute for Clinical Oncology, Saitama Cancer Center, Saitama, 362-0806, Japan.
Machiko KawamuraDepartment of Clinical Laboratory, Saitama Cancer Center, Saitama, 362-0806, Japan.
National Institute of Biomedical Innovation, Health and Nutrition · JPSaitama Cancer Center · JPEli Lilly (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kasumi-1 has played an important role in an experimental model with t(8;21) translocation, which is a representative example of leukemia cell lines. However, previous studies using Kasumi-1 show discrepancies in the genome profile. The wide use of leukemia cell lines is limited to lines that are well-characterized. The use of additional cell lines extends research to various types of leukemia, and to further explore leukemia pathogenesis, which can be achieved by uncovering the fundamental features of each cell line with accurate data. In this study, ten Kasumi cell lines established in Japan, including five that were previously unknown, have been characterized by SNP microarray and targeted sequencing. SNP genotyping suggested that the genetic ancestry in four of the ten Kasumi cell lines was not classified as Japanese but covered several different east-Asian ethnicities, suggesting that patients in Japan are genetically diverse. TP53 mutations were detected in two cell lines with complex array profiles, indicating chromosomal instability (CIN). A quantitative assessment of tumor genomes at the chromosomal level was newly introduced to reveal total DNA sizes and Scales of Genomic Alterations (SGA) for each cell line. Kasumi-1 and 6 derived from relapsed phases demonstrated high levels of SGA, implying that the level of SGA would reflect on the tumor progression and could serve as an index of CIN. Our results extend the leukemia cellular resources with an additional five cell lines and provide reference genome data with ethnic identities for the ten Kasumi cell lines.

Indexed as

Genome, HumanCell Line, TumorEthnologyGenotypeHumansLeukemiaMutationOligonucleotide Array Sequence AnalysisPolymorphism, Single NucleotideTumor Suppressor Protein p53TP53 protein, humanTumor Suppressor Protein p53Ancestry informationChromosome instabilityFusion geneTP53 alterationTumor genome size

Identifiers

PMID32180206
PMCPMC7324421
OpenAlexW3011267739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.